DelveInsight’s Menin Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, emerging menin inhibitors, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM.
Discover which indication is expected to grab the major Menin inhibitors market share @ Menin Inhibitors Market Report
Key Takeaways from the Menin Inhibitors Market Report
- In 2024, the incident population of acute myeloid leukemia in the United States was found to be around 21,250.
- Assessments as per DelveInsight showed that there were more males than females affected by acute myeloid leukemia in the United States in 2024.
- Most cases were from the age above 65 years.
- Among EU4 and the UK, Germany has the highest number of acute myeloid leukemia cases, which were around 4,680 cases in 2024.
- The leading Menin Inhibitors Companies, such as Kura Oncology, Sumitomo Pharma America, Johnson & Johnson, and others.
- Promising Menin Inhibitors Therapies such as Ziftomenib, Ziftomenib combinations with venetoclax/azacitidine, cytarabine + daunorubicin (7+3), Enzomenib (DSP-5336), Bleximenib (JNJ-75276617), and others.
Learn more about the menin inhibitors @ Menin Inhibitors Analysis
Menin Inhibitor Epidemiology Segmentation in the 7MM
- Total cases of selected indication
- Total eligible patient pool for Menin inhibitor in selected indication
- Total treated cases in selected indication
Menin Inhibitor Marketed Drugs
- REVUFORJ (revumenib): Syndax
REVUFORJ is a menin inhibitor indicated for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older. It blocks the interaction of both wild-type lysine methyltransferase 2A (KMT2A) and KMT2A fusion proteins with menin. The binding of KMT2A fusion proteins with menin is involved in KMT2A-rearranged (KMT2Ar) acute leukemias through activation of a leukemogenic transcriptional pathway. In nonclinical studies using cells that express KMT2A fusions, inhibition of the menin-KMT2A interaction with revumenib altered the transcription of multiple genes including differentiation markers.
Menin Inhibitors Emerging Drugs
- Ziftomenib: Kura Oncology
Ziftomenib is an investigational drug candidate and oral inhibitor of menin-KMT2A (MLL) for the treatment of Acute Myeloid Leukemia (AML), with the potential to combine with other targeted therapies. Ziftomenib is currently being evaluated as a monotherapy in the KOMET-001 trial and as a combination therapy with certain standards of care across multiple lines of therapy in the KOMET-007, KOMET-008 trials and KOMET-017.
To know more about menin inhibitors clinical trials, visit @ Menin Inhibitors Treatment
Menin Inhibitor Market Outlook
Menin inhibitors have emerged as a transformative class of targeted therapies in the treatment of acute leukemias, particularly for genetically defined subtypes such as NPM1-mutant and KMT2A-rearranged acute myeloid leukemia (AML). These genetic alterations are associated with poor prognosis and resistance to standard therapies, creating a high unmet need for innovative, molecularly targeted treatments. Among the front-runners in this class is REVUFORJ (revumenib), developed by Syndax, which received FDA approval in November 2024 for the treatment of relapsed or refractory acute leukemia. The drug has been granted Orphan Drug Designation and Breakthrough Therapy Designation, underscoring its clinical significance and potential to redefine standards of care in select AML subpopulations.
Menin Inhibitors Market Dynamics
The Menin Inhibitors Market is emerging as a highly promising area within oncology, particularly in the treatment of hematological malignancies. The primary driver for this market is the rising prevalence of acute leukemias, particularly acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), where mutations in KMT2A and NPM1 genes are critical disease drivers. The approval of Syndax Pharmaceuticals’ REVUFORJ as the first menin inhibitor for relapsed/refractory AML and ALL has set a benchmark, creating momentum for pipeline development and commercial interest.
Discover more about menin inhibitors in development @ Menin Inhibitors Clinical Trials
Scope of the Menin Inhibitors Market Report
- Coverage- US, EU4 (Germany, France, Italy, and Spain) the UK, and Japan
- Study Period- 2020-2034
- Forecast Period- 2025-2034
- Menin Inhibitors Companies- Syndax, Kura Oncology, Sumitomo Pharma America, Johnson & Johnson, and others.
- Menin Inhibitors Therapies- Ziftomenib, Ziftomenib combinations with venetoclax/azacitidine, cytarabine + daunorubicin (7+3), Enzomenib (DSP-5336), Bleximenib (JNJ-75276617), and others.
Explore More Information of the Menin Inhibitors Market Research Report @ Menin Inhibitors Market Access, SWOT Analysis and KOL Views
Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary of Menin Inhibitor
4. Key Events
5. Epidemiology and Market Forecast Methodology of Menin Inhibitor
6. Menin Inhibitor Market Overview at a Glance in the 7MM
7. Menin Inhibitor: Background and Overview
8. Target Patient Pool
9. Marketed Products of Menin Inhibitor
10. Emerging Therapies of Menin Inhibitor
11. Menin Inhibitor: Seven Major Market Analysis
12. Market Access and Reimbursement of Menin Inhibitors
13. SWOT Analysis of Menin Inhibitors
14. KOL Views of Menin Inhibitors
15. Unmet Needs of Menin Inhibitors
16. Appendix
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
